CMS to emphasize clinical utility of prognostic cancer tests

At Tuesday's meeting of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) to discuss prognostic tests for cancer, CMS's James Rollins said the agency will rely more heavily on clinical utility, in addition

Read the full 348 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE